Loring Wolcott & Coolidge Fiduciary Advisors LLP MA trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.1% in the 3rd quarter, HoldingsChannel reports. The fund owned 596,697 shares of the company’s stock after selling 745 shares during the period. Johnson & Johnson comprises 1.5% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings, making the stock its 24th biggest position. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Johnson & Johnson were worth $77,577,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of JNJ. Harding Loevner LP purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in shares of Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. grew its stake in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after buying an additional 5 shares in the last quarter. Mountain Capital Investment Advisors Inc purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth $124,000. Finally, Shine Investment Advisory Services Inc. purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth $177,000. 65.71% of the stock is owned by institutional investors.

JNJ has been the subject of a number of recent research reports. Goldman Sachs Group cut shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $125.00 to $130.00 in a research note on Wednesday, September 20th. Vetr raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price objective for the company in a research note on Monday, October 30th. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. BMO Capital Markets lifted their price objective on shares of Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 12th. Finally, Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $145.94.

Shares of Johnson & Johnson (NYSE JNJ) opened at $145.76 on Monday. The stock has a market cap of $391,587.16, a PE ratio of 25.31, a PEG ratio of 2.75 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a twelve month low of $110.76 and a twelve month high of $146.42.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business earned $1.68 EPS. research analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.31%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-shares-sold-by-loring-wolcott-coolidge-fiduciary-advisors-llp-ma/1807805.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.